Welminic LS Junior Syrup is a combination pharmaceutical formulation containing Levosalbutamol (0.5 mg), Ambroxol (15 mg), and Guaifenesin (50 mg) per dose, specifically designed for pediatric patients to manage respiratory conditions characterized by bronchospasm and mucus hypersecretion. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby facilitating easier breathing and relief from bronchoconstriction. Ambroxol serves as a mucolytic agent, promoting the breakdown of viscous mucus, enhancing mucociliary clearance, and improving expectoration. Guaifenesin functions as an expectorant, increasing the hydration of respiratory tract secretions, which aids in loosening phlegm and facilitating its removal from the airways. The synergistic action of these active ingredients makes Welminic LS Junior Syrup effective in the symptomatic treatment of conditions such as bronchitis, asthma, and other obstructive airway diseases in children. The syrup formulation ensures ease of administration and improved compliance in the pediatric population. It is recommended to use this medication under medical supervision, considering the appropriate dosage and duration to minimize potential adverse effects and ensure optimal therapeutic outcomes.